What Happened?
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed coverage on the stock with an "outperform" rating and a price target of $160.
The price target suggests a significant potential upside from the stock's price of $103.34 at the time of the report. The investment firm's positive outlook is based on expectations that a strengthening bioprocess market and Repligen's diverse growth drivers will lead to a return to mid-teens organic sales growth.
RBC Capital also noted several positive trends expected to ramp up, including commercial mix, biosimilars, and demand for equipment related to reshoring manufacturing.
After the initial pop the shares cooled down to $105.39, up 1.9% from previous close.
Is now the time to buy Repligen? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Repligen’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock dropped 3.2% on the news that the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.
Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales. While the sector is traditionally defensive, the hot PPI print creates a two-pronged headwind.
First, rising service-sector inflation (up 1.2% monthly) increases the operating costs for hospital systems and providers. Second, as inflation becomes a dominant political issue, drug companies' visible price-setting power makes them a primary target for regulatory intervention.
Repligen is down 35.9% since the beginning of the year, and at $105.39 per share, it is trading 38.8% below its 52-week high of $172.26 from January 2026. Investors who bought $1,000 worth of Repligen’s shares 5 years ago would now be looking at only $635.38.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
